论文部分内容阅读
目的:观察持续皮下胰岛素输注(CSII)联合动态血糖监测系统(CGMS)治疗2型糖尿病的疗效。方法:将196例2型糖尿病患者随机分为两组,CSII联合CGMS为实验组,传统多次皮下胰岛素注射(MSII)为对照组。实验组采用CGMS连续监测血糖72h,对照组采用指尖血糖仪检测血糖72h。两组均进行胰岛素治疗,比较临床疗效。结果:两组治疗后血糖均明显降低,但实验组血糖波动值小于对照组,两组比较差异有统计学意义(P<0.01)。经胰岛素治疗后,实验组低血糖的发生率为2.04%,大大低于对照组低血糖发生率(16.32%)(P<0.05)。结论:两组治疗均能达到目标血糖值,但CSII联合CGMS应用能及时发现低血糖事件,使低血糖发生率明显下降,安全性好,值得临床广泛应用。
Objective: To observe the efficacy of continuous subcutaneous insulin infusion (CSII) combined with dynamic glucose monitoring system (CGMS) in the treatment of type 2 diabetes mellitus. Methods: A total of 196 patients with type 2 diabetes mellitus were randomly divided into two groups. CSII combined with CGMS was used as the experimental group, while traditional subcutaneous insulin injection (MSII) was used as the control group. In the experimental group, blood glucose was continuously monitored by CGMS for 72 hours, while in the control group, blood glucose was measured by fingertip blood glucose meter for 72 hours. Insulin treatment were performed in both groups, and the clinical efficacy was compared. Results: The blood glucose of the two groups were significantly decreased after treatment, but the fluctuation of blood glucose in the experimental group was smaller than that of the control group. There was significant difference between the two groups (P <0.01). After insulin therapy, the incidence of hypoglycemia in the experimental group was 2.04%, which was significantly lower than that in the control group (16.32%) (P <0.05). CONCLUSION: The target blood glucose level can be reached in both groups. However, CSII combined with CGMS can detect hypoglycaemia in time and reduce the incidence of hypoglycemia. It is safe and worthy of clinical application.